1. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma
- Author
-
Yoshinao Oda, Kensuke Tanaka, Tetsuzo Tagawa, Yuichi Yamada, Atsushi Osoegawa, Taro Oba, Keisuke Kosai, Kazuki Takada, Fumihiko Kinoshita, Yuki Ono, Mototsugu Shimokawa, Yuka Oku, Masaki Mori, and Sho Wakasu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Lymphovascular invasion ,medicine.medical_treatment ,Adenocarcinoma of Lung ,chemical and pharmacologic phenomena ,Kaplan-Meier Estimate ,CD8-Positive T-Lymphocytes ,Gastroenterology ,B7-H1 Antigen ,Disease-Free Survival ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Clinical significance ,Stage (cooking) ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Aged, 80 and over ,Tumor microenvironment ,business.industry ,Standard treatment ,Hazard ratio ,Forkhead Transcription Factors ,hemic and immune systems ,Immunotherapy ,Middle Aged ,Prognosis ,Immunohistochemistry ,Progression-Free Survival ,Oncology ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Surgery ,business - Abstract
Immunotherapy has become a standard treatment option for non-small cell lung cancer (NSCLC), with the tumor microenvironment attracting significant attention. CD8 + and forkhead box protein P3 + (FoxP3 +) tumor-infiltrating lymphocytes (TILs) influence the tumor microenvironment, but the clinical significance of CD8 + and FoxP3 + TILs in stage IA lung adenocarcinoma (LAD) is poorly understood. We analyzed 203 patients with stage IA primary LAD who had undergone surgery at Kyushu University from January 2003 to December 2012. We evaluated CD8 + and FoxP3 + TILs by immunohistochemistry. We set the cutoff values at 50 cells/0.04 mm2 for CD8 + TILs and 20 cells/0.04 mm2 for FoxP3 + TILs, respectively. We divided the patients into four groups: CD8-Low/FoxP3-Low; CD8-High/FoxP3-Low; CD8-Low/FoxP3-High; and CD8-High/FoxP3-High. We compared clinical outcomes among them. Programmed cell death ligand-1 (PD-L1) expression by tumor cells was also evaluated as previously reported. Respectively, 104 (51.2%), 46 (22.7%), 22 (10.8%), and 31 (15.3%) patients were classified as CD8-Low/FoxP3-Low, CD8-High/FoxP3-Low, CD8-Low/FoxP3-High, and CD8-High/FoxP3-High. Both disease-free survival (DFS) and overall survival (OS) were significantly worse in the CD8-Low/FoxP3-High group than the other groups (5-year DFS: 66.3% vs. 90.5%; P = 0.0007, 5-year OS: 90.9% vs. 97.0%; P = 0.0077). In the multivariate analysis, CD8-Low/FoxP3-High and PD-L1 expression were independent prognostic factors of DFS, and lymphatic invasion, surgical procedure, and PD-L1 expression were independent prognostic factors of OS. CD8-Low/FoxP3-High was an independent prognostic factor of DFS (hazard ratio: 3.22; 95% confidence interval: 1.321–7.179; P = 0.0121) in stage IA LAD. Immunosuppressive conditions were associated with poor prognosis in stage IA LAD.
- Published
- 2019
- Full Text
- View/download PDF